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OBJECTIVES: To characterize the population, measure
compliance with ADA recommendations, and categorize
medication usage.
METHODS: All type 2 diabetics (N  116) visiting a
family medicine center during January 1997 as recorded
in an electronic medical record were included. Recom-
mendations for “continuing care visits” were the key data
elements retrospectively reviewed for a 1-year period
(January–December 1997). Demographic, health insur-
ance, routine office visit (e.g., weight, blood pressure, eye
and foot exams), dietary and exercise planning, disease
monitoring (e.g., self blood glucose monitoring, serum
glycated hemoglobin, serum cholesterol, urinalysis), and
detailed drug usage data were collected.
RESULTS: The sample had a mean age of 61.1 years,
was 53.4% African American and 44.8% Caucasian, and
was 69.0% female. A government-financed health insur-
ance plan insured most patients (71.5%). On the average,
a patient had about eight office visits annually. Agree-
ment with ADA recommendations of weight and blood
pressure measurements at each visit was observed in 56.0%
and 78.4% of the patients respectively. Most patients did
not have annual primary care eye (57.8%) or dilated oph-
thalmic (42.2%) or foot (73.3%) examinations docu-
mented. Agreement with laboratory recommendations
was as follows: annual total cholesterol: 59.5%; semian-
nual glycated hemoglobin: 14.7%; and annual urinalysis:
66.4%. Most patients (92) were treated with a single
drug; 23 of 116 patients used two drugs. Glyburide and
glypizide were prescribed most frequently. Compliance
with recommendations increased with age and in patients
receiving multiple versus single or no drug therapy.
CONCLUSION: Documentation of current practice
shows wide variation from ADA recommendations for
type 2 diabetics. Interventions to modify documentation
are planned.
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OBJECTIVE: Resource utilization and cost-effectiveness
data were compared in patients taking 500 mg od (AM)
levofloxacin (levo) with that of 500 mg bid clarithromy-
cin for up to 14 days.
METHODS: Patients were eligible for this multicenter,
double-blind study if they had signs and symptoms of
acute sinusitis, including X-ray evidence. Clinical response
was evaluated 2–5 days after completion of therapy and
at 1 month post therapy. Utilization parameters were de-
termined from the cost of drug, cost of the physician’s of-
fice or emergency room visit, and costs of concomitant
medications. The total cost of resources and average cost
per patient was calculated. The cost-effectiveness ratio
was determined by taking the average cost of product di-
vided by the proportion of clinical success as assessed by
investigator. The incremental cost-effectiveness ratio is
the mean cost per levo patient minus the mean cost per
clarithromycin patient, divided by the proportion of clini-
cal success of levo minus the proportion of clinical suc-
cess of clarithromycin. Cost-minimization was calculated
from the mean cost per levo patient minus the mean cost
per clarithromycin patient.
RESULTS: 191 patients had resource utilization data, 98
in the levo group and 93 in the clarithromycin group. The
total cost of resources was $11,566.24 for levo and
$12,635.14 for clarithromycin. Average cost per patient
was $119.24 for levo and $135.86 for clarithromycin. The
cost-effectiveness ratio for levo was 1.3, and for clarithro-
mycin 1.5. Because clinical success rates were similar a
cost minimization analysis was performed. The result was
16.6. The incremental cost-effectiveness ratio was 	50.5.
CONCLUSION: In patients with similar clinical success
rates, this study shows that levo 500 mg od is more cost-
effective than 500 mg bid clarithromycin.
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